Argitalpenak (61) Marta Llanos Muñoz argitalpenak

2023

  1. A genetic profiling guideline to support diagnosis and clinical management of lymphomas

    Clinical and Translational Oncology

  2. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

    Nature Communications, Vol. 14, Núm. 1

  3. Monitoring of Circulating Tumor DNA Predicts Response to Treatment and Early Progression in Follicular Lymphoma: Results of a Prospective Pilot Study

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 29, Núm. 1, pp. 209-220

  4. SEOM-GOTEL clinical guidelines on diffuse large B cell lymphoma (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2749-2758

2022

  1. Evolution of RAS Mutations in Cell-Free DNA of Patients with Tissue RAS Wild-Type Metastatic Colorectal Cancer Receiving First-Line Treatment: The PERSEIDA Study

    Cancers, Vol. 14, Núm. 24

  2. External Validity of Somatostatin Analogs Trials in Advanced Neuroendocrine Neoplasms: The GETNE-TRASGU Study

    Neuroendocrinology, Vol. 112, Núm. 1, pp. 88-100

  3. Initial clinical and treatment patterns of advanced differentiated thyroid cancer: ERUDIT study

    European Thyroid Journal, Vol. 11, Núm. 5

2021

  1. First-Line Biological Agents Plus Chemotherapy in Older Patients with Metastatic Colorectal Cancer: A Retrospective Pooled Analysis

    Drugs and Aging, Vol. 38, Núm. 3, pp. 219-231

  2. Proposal and validation of a method to classify genetic subtypes of diffuse large B cell lymphoma

    Scientific Reports, Vol. 11, Núm. 1

  3. Usefulness of an immunohistochemical score in advanced pancreatic neuroendocrine tumors treated with CAPTEM or everolimus

    Pancreatology, Vol. 21, Núm. 1, pp. 215-223

2019

  1. Consolidation treatment with yttrium-90 ibritumomab tiuxetan after new induction regimen in advanced stage follicular lymphoma: update results from the Spanish Lymphoma Oncology Group trial after a median follow-up of 8.5-years

    Leukemia and Lymphoma

  2. Efficacy of the combination of rituximab-bendamustine as a second-line treatment in patients with follicular lymphoma who progress after immunochemotherapy: a phase II trial of the Spanish Lymphoma Oncology Group

    Leukemia and Lymphoma

  3. Prediction of Progression-Free Survival in Patients With Advanced, Well-Differentiated, Neuroendocrine Tumors Being Treated With a Somatostatin Analog: The GETNE-TRASGU Study

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 37, Núm. 28, pp. 2571-2580

  4. Transformed follicular lymphoma in the rituximab era: A report from the Spanish Lymphoma Oncology Group

    Hematological Oncology, Vol. 37, Núm. 2, pp. 143-150

  5. Unraveling transformation of follicular lymphoma to diffuse large B-cell lymphoma

    PLoS ONE, Vol. 14, Núm. 2

2018

  1. Biomarkers and polymorphisms in pancreatic neuroendocrine tumors treated with sunitinib

    Oncotarget, Vol. 9, Núm. 97, pp. 36894-36905

  2. Effect of UGT, SLCO, ABCB and ABCC polymorphisms on irinotecan toxicity

    Medicina Clinica, Vol. 151, Núm. 11, pp. 425-430

  3. Efficacy and safety of vandetanib for patients with advanced and progressive medullary thyroid cancer (MTC) as systemic treatment beyond first-line therapy

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii476

  4. First-line treatment outcomes according to cfDNA analysis of RAS mutation status in metastatic colorectal cancer (mCRC) patients (pts): PERSEIDA study

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii183

  5. Neuroendocrine Tumor Heterogeneity Adds Uncertainty to the World Health Organization 2010 Classification: Real-World Data from the Spanish Tumor Registry (R-GETNE)

    Oncologist, Vol. 23, Núm. 4, pp. 422-432